Skip to main content

ESTUDIO DE LA GLICOSILACION DE PLASMODIUM FALCIPARUM Y OTRAS VIAS METABOLICAS ASOCIADAS PARA EL DISEÑO DE NUEVAS ESTRATEGIAS CONTRA LA MALARIA

PID2019-110810RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia

  • Karachaliou, Marianna|||0000-0002-3014-0747
  • Espinosa, Ana|||0000-0001-7399-3267
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Blay, Natalia|||0000-0002-7160-8529
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Iraola-Guzmán, Susana|||0000-0003-3359-1241
  • Rubio, Rocio
  • Vidal, Marta
  • Jiménez, Alfons
  • Bañuls, Marc
  • Aguilar, Ruth|||0000-0003-3277-3107
  • Garcia-Aymerich, Judith|||0000-0002-7097-4586
  • Dobaño Lazaro, Carlota|||0000-0002-6751-4060
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Moncunill, Gemma|||0000-0001-5105-9836
  • de Cid, Rafael|||0000-0003-3579-6777
Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment. Methods: The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses. Results: Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels. Conclusions: These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Long-term exposure to air pollution and COVID-19 vaccine antibody response in a general population cohort (COVICAT Study, Catalonia)

  • Kogevinas, Manolis
  • Karachaliou, Marianna
  • Espinosa, Ana
  • Aguilar, Ruth
  • Castaño Vinyals, Gemma
  • García Aymerich, Judith
  • Rubio, Rocío
  • Jiménez, Alfons
  • Vidal, Marta
  • Izquierdo, Luis
  • Cirach, Marta
  • Nieuwenhuijsen, Mark J.
  • Dadvand, Payam
  • Straif, Kurt
  • Moncunill, Gemma
  • Dobaño, Carlota
  • Tonne, Cathryn
Background: Ambient air pollution has been associated with COVID-19 disease severity and antibody response induced by infection. Objectives: We examined the association between long-term exposure to air pollution and vaccine-induced antibody response. Methods: This study was nested in an ongoing population-based cohort, COVICAT, the GCAT-Genomes for Life cohort, in Catalonia, Spain, with multiple follow-ups. We drew blood samples in 2021 from 1,090 participants of 2,404 who provided samples in 2020, and we included 927 participants in this analysis. We measured immunoglobulin M (IgM), IgG, and IgA antibodies against five viral-target antigens, including receptor-binding domain (RBD), spike-protein (S), and segment spike-protein (S2) triggered by vaccines available in Spain. We estimated prepandemic (2018-2019) exposure to fine particulate matter [PM ≤ 2.5μm in aerodynamic diameter (PM2.5)], nitrogen dioxide (NO2), black carbon (BC), and ozone (O3) using Effects of Low-Level Air Pollution: A Study in Europe (ELAPSE) models. We adjusted estimates for individual- and area-level covariates, time since vaccination, and vaccine doses and type and stratified by infection status. We used generalized additive models to explore the relationship between air pollution and antibodies according to days since vaccination. Results: Among vaccinated persons not infected by SARS-CoV-2 (n=632), higher prepandemic air pollution levels were associated with a lower vaccine antibody response for IgM (1 month post vaccination) and IgG. Percentage change in geometric mean IgG levels per interquartile range of PM2.5 (1.7μg/m3) were −8.1 (95% CI: −15.9, 0.4) for RBD,−9.9 (−16.2, −3.1) for S, and −8.4 (−13.5, −3.0) for S2. We observed a similar pattern for NO2 and BC and an inverse pattern for O3. Differences in IgG levels by air pollution levels persisted with time since vaccination. We did not observe an association of air pollution with vaccine antibody response among participants with prior infection (n=295). Discussion: Exposure to air pollution was associated with lower COVID-19 vaccine antibody response. The implications of this association on the risk of breakthrough infections require further investigation. https://doi.org/10.1289/EHP11989., We acknowledge support from the Incentius a l’Avaluació de Centres CERCA (in_CERCA); EIT HEALTH BP2020-20873-Certify.Health; Fundació Privada Daniel Bravo Andreu; Spanish Ministry of Science & Innovation (PID2019-110810RB-I00 grant); the Spanish State Research Agency and Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), the Instituto de Salud Carlos III (PI17/01555) and the Generalitat de Catalunya through the CERCA Program. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP. IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Department of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). G.M. is supported by RYC2020-029886-I/AEI/10.13039/501100011033, co-funded by European Social Fund. B.C. is supported by ISCIII national grant PI18/01512. R.R. is supported by the Health Department, Catalan Government (PERIS SLT017/20/000224). The full list of the investigators who contributed to the generation of the GCAT data is available from http://www.genomesforlife.com. Data are available from the authors.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sustained seropositivity up to 20.5 months after COVID-19

  • Dobaño, Carlota
  • Ramírez Morros, Anna Maria
  • Alonso, Selena
  • Rubio, Rocío
  • Ruiz-Olalla, Gemma
  • Vidal Alaball, Josep
  • Macià, Dídac
  • Miró Catalina, Queralt
  • Vidal, Marta
  • Fuster Casanovas, Aina
  • Prados de la Torre, Esther
  • Barrios, Diana
  • Jiménez, Alfons
  • Zanoncello, Jasmina
  • Rodrigo Melero, Natalia
  • Carolis, Carlo
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Moncunill, Gemma
  • Ruiz-Comellas, Anna
This study evaluated the persistence of IgM, IgA, and IgG to SARS-CoV-2 spike and nucleocapsid antigens up to 616 days since the onset of symptoms in a longitudinal cohort of 247 primary health care workers from Barcelona, Spain, followed up since the start of the pandemic. The study also assesses factors affecting antibody levels, including comorbidities and the responses to variants of concern as well as the frequency of reinfections. Despite a gradual and significant decline in antibody levels with time, seropositivity to five SARS-CoV-2 antigens combined was always higher than 90% over the whole study period. In a subset of 23 participants who had not yet been vaccinated by November 2021, seropositivity remained at 95.65% (47.83% IgM, 95.65% IgA, 95.65% IgG). IgG seropositivity against Alpha and Delta predominant variants was comparable to that against the Wuhan variant, while it was lower for Gamma and Beta (minority) variants and for IgA and IgM. Antibody levels at the time point closest to infection were associated with age, smoking, obesity, hospitalization, fever, anosmia/hypogeusia, chest pain, and hypertension in multivariable regression models. Up to 1 year later, just before the massive roll out of vaccination, antibody levels were associated with age, occupation, hospitalization, duration of symptoms, anosmia/hypogeusia, fever, and headache. In addition, tachycardia and cutaneous symptoms associated with slower antibody decay, and oxygen supply with faster antibody decay. Eight reinfections (3.23%) were detected in low responders, which is consistent with a sustained protective role for anti-spike naturally acquired antibodies. Stable persistence of IgG and IgA responses and cross-recognition of the predominant variants circulating in the 2020-2021 period indicate long-lasting and largely variant-transcending humoral immunity in the initial 20.5 months of the pandemic, in the absence of vaccination., The study received support from the Fundació Privada Daniel Bravo Andreu. Development of SARS-CoV-2 RBD was partially supported by the NIAID CEIRS contract HHSN272201400008C. L.I. work was supported by PID2019-110810RB-I00. E.P. was supported by a grant from the Junta de Andalucía/EU. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. Funders were not involved in the study conduct, manuscript preparation, or submission.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia

  • Karachaliou, Marianna
  • Espinosa, Ana
  • Farré, Xavier
  • Blay, Natalia
  • Castaño Vinyals, Gemma
  • Iraola Guzmán, Susana
  • Rubio, Rocío
  • Vidal, Marta
  • Jiménez, Alfons
  • Bañuls, Marc
  • Aguilar, Ruth
  • García Aymerich, Judith
  • Dobaño, Carlota
  • Kogevinas, Manolis
  • Moncunill, Gemma
  • Cid Ibeas, Rafael de
Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment. Methods: The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses. Results: Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels. Conclusions: These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation., This work was funded by Incentius a l'Avaluació de Centres CERCA (in_ CERCA); EIT HEALTH BP2020-20873-Certify.Health.; Fundació Privada Daniel Bravo Andreu; PID2019-110810RB-I00 grant (Spanish Ministry of Science & Innovation). Rocio Rubio had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S). ISGlobal and IGTP receive support from the Generalitat de Catalunya through the CERCA Program. GCAT was funded by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026) and have additional suport by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529), National Grant PI18/01512 and VEIS project (001-P-001647) (co-funded by European Regional Development Fund (ERDF), “A way to build Europe”). This study was carried out using anonymized data provided by the Catalan Agency for Quality and Health Assessment, within the framework of the PADRIS Program. The funders had no role in the study design, data collection and analysis, interpretation of data, preparation of the manuscript, and decision to publish.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain

  • Karachaliou, Marianna
  • Moncunill, Gemma
  • Espinosa, Ana
  • Castaño Vinyals, Gemma
  • Jiménez, Alfons
  • Vidal, Marta
  • Santano, Rebeca
  • Barrios, Diana
  • Jiménez, Alfons
  • Puyol, Laura
  • Mayer, Leonie
  • Rubio, Rocío
  • O'Callaghan-Gordo, Cristina
  • Fossati, Serena
  • Rivas, Ioar
  • Vrijheid, Martine
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Basagaña Flores, Xavier
  • García Aymerich, Judith
  • Dobaño, Carlota
  • Kogevinas, Manolis
Sparse data exist on the complex natural immunity to SARS-CoV-2 at the population level. We applied a well-validated multiplex serology test in 5000 participants of a general population study in Catalonia in blood samples collected from end June to mid November 2020. Based on responses to fifteen isotype-antigen combinations, we detected a seroprevalence of 18.1% in adults (n = 4740), and modeled extrapolation to the general population of Catalonia indicated a 15.3% seroprevalence. Antibodies persisted up to 9 months after infection. Immune profiling of infected individuals revealed that with increasing severity of infection (asymptomatic, 1-3 symptoms, ≥ 4 symptoms, admitted to hospital/ICU), seroresponses were more robust and rich with a shift towards IgG over IgA and anti-spike over anti-nucleocapsid responses. Among seropositive participants, lower antibody levels were observed for those ≥ 60 years vs < 60 years old and smokers vs non-smokers. Overweight/obese participants vs normal weight had higher antibody levels. Adolescents (13-15 years old) (n = 260) showed a seroprevalence of 11.5%, were less likely to be tested seropositive compared to their parents and had dominant anti-spike rather than anti-nucleocapsid IgG responses. Our study provides an unbiased estimate of SARS-CoV-2 seroprevalence in Catalonia and new evidence on the durability and heterogeneity of post-infection immunity., We thank the volunteers who participate in the cohort studies, all the workers in different facilities of the Blood and Tissue Bank for sample recruitment, Jordi Chi for antigen expression and purification and Victor Moreno for data collection in MCC study. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundacio IGTP. IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). Full list of the investigators who contributed to the generation of the GCAT data is available from www.genomesforlife.com. LeRAgs is supported by Instituto de Salud Carlos III (PI17/01555). Beatriz Cortés is supported by ISCIII national Grant PI18/01512. Ioar Rivas is supported from the postdoctoral fellowships programme Beatriu de Pinós (2018 BP 00114), funded by the Secretary of Universities and Research (Government of Catalonia) and by the Horizon 2020 programme of research and innovation of the European Union under the Marie Sklodowska-Curie Grant Agreement No 801370. This work was funded by Incentius a l’Avaluació de Centres CERCA (in_CERCA); EIT HEALTH BP2020-20873-Certify.Health.; Fundació Privada Daniel Bravo Andreu; PID2019-110810RB-I00 Grant (Spanish Ministry of Science & Innovation). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S). ISGlobal and IGTP receive support from the Generalitat de Catalunya through the CERCA Program. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia

  • Kogevinas, Manolis
  • Karachaliou, Marianna
  • Espinosa, Ana
  • Iraola Guzmán, Susana
  • Castaño Vinyals, Gemma
  • Delgado-Ortiz, Laura
  • Farré, Xavier
  • Blay, Natalia
  • Pearce, Neil E.
  • Bosch de Basea i Gómez, Magda, 1982-
  • Alonso Nogués, Eva
  • Dobaño, Carlota
  • Moncunill, Gemma
  • Cid Ibeas, Rafael de
  • García Aymerich, Judith
Background: Long-COVID has mostly been investigated in clinical settings. We aimed to assess the risk, subtypes, persistence, and determinants of long-COVID in a prospective population-based study of adults with a history of SARS-CoV-2 infection in Catalonia. Methods: We examined 2764 infected individuals from a population-based cohort (COVICAT) established before the pandemic and followed up three times across the pandemic (2020, 2021, 2023). We assessed immunoglobulin (Ig)G levels against SARS-CoV-2, clinical, vaccination, sociodemographic, and lifestyle factors. Long-COVID risk and subtypes were defined based on participant-reported symptoms and electronic health records. We identified a total of 647 long-COVID cases and compared them with 2117 infected individuals without the condition. Results: Between 2021 and 2023, 23% of infected subjects developed long-COVID symptoms. In 56% of long-COVID cases in 2021, symptoms persisted for 2 years. Long-COVID presented clinically in three subtypes, mild neuromuscular, mild respiratory, and severe multi-organ. The latter was associated with persistent long-COVID. Risk was higher among females, participants under 50 years, of low socioeconomic status, severe COVID-19 infection, elevated pre-vaccination IgG levels, obesity, and prior chronic disease, particularly asthma/chronic obstructive pulmonary disease and mental health conditions. A lower risk was associated to pre-infection vaccination, infection after omicron became the dominant variant, higher physical activity levels, and sleeping 6-8 h. Vaccination during the 3 months post-infection was also protective against long-COVID. Conclusions: Long-COVID persisted for up to 2 years in half of the cases, and risk was influenced by multiple factors., We acknowledge support from the Horizon Europe END-VOC (grant agreement no. 101046314), Spanish Ministry of Science & Innovation (PID2019-110810RB-I00 grant); the Spanish State Research Agency and Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), the Instituto de Salud Carlos III (PI17/01555, PI18/01512), the La MaratoTV3 Foundation (167/C/2021), the Generalitat de Catalunya through the CERCA Program and the Fundació Privada Daniel Bravo Andreu; Xavier Farré is supported by VEIS project (001-P-001647, co-funded by European Regional Development Fund (ERDF). G.M. is supported by RYC 2020–029886-I/AEI/https://doi.org/10.13039/501100011033, co-funded by the European Social Fund (ESF). We acknowledge support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and cytokine profile

  • Rubio, Rocío
  • Aguilar, Ruth
  • Bustamante Pineda, Mariona
  • Muñoz, Erica
  • Vázquez-Santiago, Miquel
  • Santano, Rebeca
  • Vidal, Marta
  • Rodrigo Melero, Natalia
  • Parras, Daniel
  • Serra, Pau
  • Santamaria, Pere
  • Carolis, Carlo
  • Izquierdo, Luis
  • Gómez Roig, Ma. Dolores
  • Dobaño, Carlota
  • Moncunill, Gemma
  • Mazarico, Edurne
SARS-CoV-2 infected pregnant women are at increased risk of severe COVID-19 than non-pregnant women and have a higher risk of adverse pregnancy outcomes like intrauterine/fetal distress and preterm birth. However, little is known about the impact of SARS-CoV-2 infection on maternal and neonatal immunological profiles. In this study, we investigated the inflammatory and humoral responses to SARS-CoV-2 in maternal and cord blood paired samples. Thirty-six pregnant women were recruited at delivery at Hospital Sant Joan de Déu, Barcelona, Spain, between April-August 2020, before having COVID-19 available vaccines. Maternal and pregnancy variables, as well as perinatal outcomes, were recorded in questionnaires. Nasopharyngeal swabs and maternal and cord blood samples were collected for SARS-CoV-2 detection by rRT-PCR and serology, respectively. We measured IgM, IgG and IgA levels to 6 SARS-CoV-2 antigens (spike [S], S1, S2, receptor-binding domain [RBD], nucleocapsid [N] full-length and C-terminus), IgG to N from 4 human coronaviruses (OC43, HKU1, 229E and NL63), and the concentrations of 30 cytokines, chemokines and growth factors by Luminex. Mothers were classified as infected or non-infected based on the rRT-PCR and serology results. Sixty-four % of pregnant women were infected with SARS-CoV-2 (positive by rRT-PCR during the third trimester and/or serology just after delivery). None of the newborns tested positive for rRT-PCR. SARS-CoV-2 infected mothers had increased levels of virus-specific antibodies and several cytokines. Those with symptoms had higher cytokine levels. IFN-α was increased in cord blood from infected mothers, and in cord blood of symptomatic mothers, EGF, FGF, IL-17 and IL-15 were increased, whereas RANTES was decreased. Maternal IgG and cytokine levels showed positive correlations with their counterparts in cord blood. rRT-PCR positive mothers showed lower transfer of SARS-CoV-2-specific IgGs, with a stronger effect when infection was closer to delivery. SARS-CoV-2 infected mothers carrying a male fetus had higher antibody levels and higher EGF, IL-15 and IL-7 concentrations. Our results show that SARS-CoV-2 infection during the third trimester of pregnancy induces a robust antibody and cytokine response at delivery and causes a significant reduction of the SARS-CoV-2-specific IgGs transplacental transfer, with a stronger negative effect when the infection is closer to delivery., This work was supported by the Fundació Privada Daniel Bravo Andreu. RR had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). LI work was supported by the PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. We acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Multiplex antibody analysis of IgM, IgA and IgG to SARS-CoV-2 in saliva and serum from infected children and their close contacts

  • Dobaño, Carlota
  • Alonso, Selena
  • Vidal, Marta
  • Jiménez, Alfons
  • Rubio, Rocío
  • Santano, Rebeca
  • Barrios, Diana
  • Puyol, Laura
  • Baró, Bàrbara
  • Millat-Martínez, Pere
  • Ajanovic, Sara
  • Balanza, Núria
  • Arias, Sara
  • Rodrigo Melero, Natalia
  • Carolis, Carlo
  • Bassat, Quique
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Moncunill, Gemma
COVID-19 affects children to a lesser extent than adults but they can still get infected and transmit SARS-CoV-2 to their contacts. Field deployable non-invasive sensitive diagnostic techniques are needed to evaluate the infectivity dynamics of SARS-CoV-2 in pediatric populations and guide public health interventions, particularly if this population is not fully vaccinated. We evaluated the utility of high-throughput Luminex assays to quantify saliva IgM, IgA and IgG antibodies against five SARS-CoV-2 spike (S) and nucleocapsid (N) antigens in a contacts and infectivity longitudinal study in 122 individuals (52 children and 70 adults). We compared saliva versus serum/plasma samples in infected children and adults diagnosed by weekly RT-PCR over 35 days (n=62), and those who consistently tested negative over the same follow up period (n=60), in the Summer of 2020 in Barcelona, Spain. Saliva antibody levels in SARS-CoV-2 RT-PCR positive individuals were significantly higher than in negative individuals and correlated with those measured in sera/plasmas. Asymptomatic infected individuals had higher levels of anti-S IgG than symptomatic individuals, suggesting a protective anti-disease role for antibodies. Higher anti-S IgG and IgM levels in serum/plasma and saliva, respectively, in infected children compared to infected adults could also be related to stronger clinical immunity in them. Among infected children, males had higher levels of saliva IgG to N and RBD than females. Despite overall correlation, individual clustering analysis suggested that responses that may not be detected in blood could be patent in saliva, and vice versa. In conclusion, measurement of SARS-CoV-2-specific saliva antibodies should be considered as a complementary non-invasive assay to serum/plasma to determine COVID-19 prevalence and transmission in pediatric populations before and after vaccination campaigns., We are indebted to the Biobanc de l’Hospital Infantil Sant Joan de Déu per a la Investigació for the sample and data procurement. Some serum/plasma samples were tested against RBD protein produced in lentivirus by the P. Santamaria lab, IDIBAPS, and Jordi Chi contributed for production of N proteins (through PID2019-110810RB-I00 grant to LI).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

RBD-Based ELISA and luminex predict Anti-SARS-CoV-2 surrogate-neutralizing activity in two longitudinal cohorts of German and Spanish health care workers

  • Aguilar, Ruth
  • Vidal, Marta
  • Rubio, Rocío
  • Jiménez, Alfons
  • Carolis, Carlo
  • Mayor, Alfredo
  • Izquierdo, Luis
  • Garcia Basteiro, Alberto L.
  • Moncunill, Gemma
  • Dobaño, Carlota
  • Gerhard, Markus
The ability of antibodies to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important correlate of protection. For routine evaluation of protection, however, a simple and cost-efficient anti-SARS-CoV-2 serological assay predictive of serum neutralizing activity is needed. We analyzed clinical epidemiological data and blood samples from two cohorts of health care workers in Barcelona and Munich to compare several immunological readouts for evaluating antibody levels that could be surrogates of neutralizing activity. We measured IgG levels against SARS-CoV-2 spike protein (S), its S2 subunit, the S1 receptor binding domain (RBD), and the full length and C terminus of nucleocapsid (N) protein by Luminex, and against RBD by enzyme-linked immunosorbent assay (ELISA), and assessed those as predictors of plasma surrogate-neutralizing activity measured by a flow cytometry assay. In addition, we determined the clinical and demographic factors affecting plasma surrogate-neutralizing capacity. Both cohorts showed a high positive correlation between IgG levels to S antigen, especially to RBD, and the levels of plasma surrogate-neutralizing activity, suggesting RBD IgG as a good correlate of plasma neutralizing activity. Symptomatic infection, with symptoms such as loss of taste, dyspnea, rigors, fever and fatigue, was positively associated with anti-RBD IgG positivity by ELISA and Luminex, and with plasma surrogate-neutralizing activity. Our serological assays allow for the prediction of serum neutralization activity without the cost, hazards, time, and expertise needed for surrogate or conventional neutralization assays. Once a cutoff is established, these relatively simple high-throughput antibody assays will provide a fast and cost-effective method of assessing levels of protection from SARS-CoV-2 infection. IMPORTANCE Neutralizing antibody titers are the best correlate of protection against SARS-CoV-2. However, current tests to measure plasma or serum neutralizing activity do not allow high-throughput screening at the population level. Serological tests could be an alternative if they are proved to be good predictors of plasma neutralizing activity. In this study, we analyzed the SARS-CoV-2 serological profiles of two cohorts of health care workers by applying Luminex and ELISA in-house serological assays. Correlations of both serological tests were assessed between them and with a flow cytometry assay to determine plasma surrogate-neutralizing activity. Both assays showed a high positive correlation between IgG levels to S antigens, especially RBD, and the levels of plasma surrogate-neutralizing activity. This result suggests IgG to RBD as a good correlate of plasma surrogate-neutralizing activity and indicates that serology of IgG to RBD could be used to assess levels of protection from SARS-CoV-2 infection., This work was supported by the European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Program. The study was also supported by the Institut de Salut Global de Barcelona (ISGlobal) internal funds, in-kind contributions from Hospital Clínic de Barcelona and the Fundació Privada Daniel Bravo Andreu. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. L.I. was supported by the PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C).
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Plasmodium falciparum apicomplexan-specific glucosamine-6-phosphate n-acetyltransferase is key for amino sugar metabolism and asexual blood stage development

  • Planas, Antoni
  • Leivar, Pablo
  • Chi, Jordi
  • Cova, Marta
  • De las Rivas, Matilde
  • Medina, Ana
  • Junqueira Borges, Rafael
  • Usón, Isabel
  • Hurtado-Guerrero, Ramón
  • Izquierdo, Luis
ABSTRACT UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1. The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria., IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite’s ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

RTS,S/AS02A Malaria Vaccine-Induced IgG Responses Equally Recognize Native-Like Fucosylated and Nonfucosylated <i>Plasmodium falciparum</i> Circumsporozoite Proteins

  • Jairoce, Chenjerai
  • Macià, Dídac
  • Torres-Yaguana, Jorge P
  • Mayer, Leonie
  • Vidal, Marta
  • Santano, Rebeca
  • Hurtado-Guerrero, Ramón
  • Reiter, Karine
  • Narum, David L
  • Lopez-Gutierrez, Borja
  • Hamerly, Timothy
  • Sacarlal, Jahit
  • Aguilar, Ruth
  • Dinglasan, Rhoel R
  • Moncunill, Gemma
  • Izquierdo, Luis
  • Dobaño, Carlota
The RTS,S/AS02A malaria vaccine is based on the Plasmodium falciparum circumsporozoite protein (PfCSP), which is O-fucosylated on the sporozoite surface. We determined whether RTS,S/AS02A-induced immunoglobulin G (IgG) antibodies recognize vaccine-like nonfucosylated PfCSP better than native-like fucosylated PfCSP. Similar to previous vaccine trials, RTS,S/AS02A vaccination induced high anti-PfCSP IgG levels associated with malaria protection. IgG recognition of nonfucosylated and fucosylated PfCSP was equivalent, suggesting that PfCSP fucosylation does not affect antibody recognition.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Machine learning-based prediction of tear osmolarity for contact lens practice

  • Garaszczuk, Izabela K.
  • Romanos-Ibanez, Maria
  • Consejo, Alejandra
Purpose: This study addressed the utilisation of machine learning techniques to estimate tear osmolarity, a clinically significant yet challenging parameter to measure accurately. Elevated tear osmolarity has been observed in contact lens wearers and is associated with contact lens‐induced dry eye, a common cause of discomfort leading to discontinuation of lens wear. Methods: The study explored machine learning, regression and classification techniques to predict tear osmolarity using routine clinical parameters. The data set consisted of 175 participants, primarily healthy subjects eligible for soft contact lens wear. Various clinical assessments were performed, including symptom assessment with the Ocular Surface Disease Index and 5‐Item Dry Eye Questionnaire (DEQ‐5), tear meniscus height (TMH), tear osmolarity, non‐invasive keratometric tear film break‐up time (NIKBUT), ocular redness, corneal and conjunctival fluorescein staining and Meibomian glands loss. Results : The results revealed that simple linear regression was insufficient for accurate osmolarity prediction. Instead, more advanced regression models achieved a moderate level of predictive power, explaining approximately 32% of the osmolarity variability. Notably, key predictors for osmolarity included NIKBUT, TMH, ocular redness, Meibomian gland coverage and the DEQ‐5 questionnaire. In classification tasks, distinguishing between low (<299 mOsmol/L), medium (300–307 mOsmol/L) and high osmolarity (>308 mOsmol/L) levels yielded an accuracy of approximately 80%. Key parameters for classification were similar to those in regression models, emphasising the importance of NIKBUT, TMH, ocular redness, Meibomian glands coverage and the DEQ‐5 questionnaire. Conclusions: This study highlights the potential benefits of integrating machine learning into contact lens research and practice. It suggests the clinical utility of assessing Meibomian glands and NIKBUT in contact lens fitting and follow‐up visits. Machine learning models can optimise contact lens prescriptions and aid in early detection of conditions like dry eye, ultimately enhancing ocular health and the contact lens wearing experience.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia

  • Kogevinas, Manolis
  • Karachaliou, Marianna
  • Espinosa, Ana
  • Iraola Guzmán, Susana
  • Castaño Vinyals, Gemma
  • Delgado-Ortiz, Laura
  • Farré, Xavier
  • Blay, Natalia
  • Pearce, Neil E.
  • Bosch de Basea i Gómez, Magda, 1982-
  • Alonso Nogués, Eva
  • Dobaño, Carlota
  • Moncunill, Gemma
  • Cid Ibeas, Rafael de
  • García Aymerich, Judith
Background: Long-COVID has mostly been investigated in clinical settings. We aimed to assess the risk, subtypes, persistence, and determinants of long-COVID in a prospective population-based study of adults with a history of SARS-CoV-2 infection in Catalonia. Methods: We examined 2764 infected individuals from a population-based cohort (COVICAT) established before the pandemic and followed up three times across the pandemic (2020, 2021, 2023). We assessed immunoglobulin (Ig)G levels against SARS-CoV-2, clinical, vaccination, sociodemographic, and lifestyle factors. Long-COVID risk and subtypes were defined based on participant-reported symptoms and electronic health records. We identified a total of 647 long-COVID cases and compared them with 2117 infected individuals without the condition. Results: Between 2021 and 2023, 23% of infected subjects developed long-COVID symptoms. In 56% of long-COVID cases in 2021, symptoms persisted for 2 years. Long-COVID presented clinically in three subtypes, mild neuromuscular, mild respiratory, and severe multi-organ. The latter was associated with persistent long-COVID. Risk was higher among females, participants under 50 years, of low socioeconomic status, severe COVID-19 infection, elevated pre-vaccination IgG levels, obesity, and prior chronic disease, particularly asthma/chronic obstructive pulmonary disease and mental health conditions. A lower risk was associated to pre-infection vaccination, infection after omicron became the dominant variant, higher physical activity levels, and sleeping 6-8 h. Vaccination during the 3 months post-infection was also protective against long-COVID. Conclusions: Long-COVID persisted for up to 2 years in half of the cases, and risk was influenced by multiple factors., We acknowledge support from the Horizon Europe END-VOC (grant agreement no. 101046314), Spanish Ministry of Science & Innovation (PID2019-110810RB-I00 grant); the Spanish State Research Agency and Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), the Instituto de Salud Carlos III (PI17/01555, PI18/01512), the La MaratoTV3 Foundation (167/C/2021), the Generalitat de Catalunya through the CERCA Program and the Fundació Privada Daniel Bravo Andreu; Xavier Farré is supported by VEIS project (001-P-001647, co-funded by European Regional Development Fund (ERDF). G.M. is supported by RYC 2020–029886-I/AEI/https://doi.org/10.13039/501100011033, co-funded by the European Social Fund (ESF). We acknowledge support from the grant CEX2023-0001290-S funded by MCIN/AEI/ https://doi.org/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain

  • Karachaliou, Marianna
  • Moncunill, Gemma
  • Espinosa, Ana
  • Castaño Vinyals, Gemma
  • Jiménez, Alfons
  • Vidal, Marta
  • Santano, Rebeca
  • Barrios, Diana
  • Jiménez, Alfons
  • Puyol, Laura
  • Mayer, Leonie
  • Rubio, Rocío
  • O&apos;Callaghan-Gordo, Cristina
  • Fossati, Serena
  • Rivas, Ioar
  • Vrijheid, Martine
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Basagaña Flores, Xavier
  • García Aymerich, Judith
  • Dobaño, Carlota
  • Kogevinas, Manolis
Sparse data exist on the complex natural immunity to SARS-CoV-2 at the population level. We applied a well-validated multiplex serology test in 5000 participants of a general population study in Catalonia in blood samples collected from end June to mid November 2020. Based on responses to fifteen isotype-antigen combinations, we detected a seroprevalence of 18.1% in adults (n = 4740), and modeled extrapolation to the general population of Catalonia indicated a 15.3% seroprevalence. Antibodies persisted up to 9 months after infection. Immune profiling of infected individuals revealed that with increasing severity of infection (asymptomatic, 1-3 symptoms, ≥ 4 symptoms, admitted to hospital/ICU), seroresponses were more robust and rich with a shift towards IgG over IgA and anti-spike over anti-nucleocapsid responses. Among seropositive participants, lower antibody levels were observed for those ≥ 60 years vs < 60 years old and smokers vs non-smokers. Overweight/obese participants vs normal weight had higher antibody levels. Adolescents (13-15 years old) (n = 260) showed a seroprevalence of 11.5%, were less likely to be tested seropositive compared to their parents and had dominant anti-spike rather than anti-nucleocapsid IgG responses. Our study provides an unbiased estimate of SARS-CoV-2 seroprevalence in Catalonia and new evidence on the durability and heterogeneity of post-infection immunity., We thank the volunteers who participate in the cohort studies, all the workers in different facilities of the Blood and Tissue Bank for sample recruitment, Jordi Chi for antigen expression and purification and Victor Moreno for data collection in MCC study. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundacio IGTP. IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). Full list of the investigators who contributed to the generation of the GCAT data is available from www.genomesforlife.com. LeRAgs is supported by Instituto de Salud Carlos III (PI17/01555). Beatriz Cortés is supported by ISCIII national Grant PI18/01512. Ioar Rivas is supported from the postdoctoral fellowships programme Beatriu de Pinós (2018 BP 00114), funded by the Secretary of Universities and Research (Government of Catalonia) and by the Horizon 2020 programme of research and innovation of the European Union under the Marie Sklodowska-Curie Grant Agreement No 801370. This work was funded by Incentius a l’Avaluació de Centres CERCA (in_CERCA); EIT HEALTH BP2020-20873-Certify.Health.; Fundació Privada Daniel Bravo Andreu; PID2019-110810RB-I00 Grant (Spanish Ministry of Science & Innovation). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S). ISGlobal and IGTP receive support from the Generalitat de Catalunya through the CERCA Program. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RBD-Based ELISA and luminex predict Anti-SARS-CoV-2 surrogate-neutralizing activity in two longitudinal cohorts of German and Spanish health care workers

  • Aguilar, Ruth
  • Vidal, Marta
  • Rubio, Rocío
  • Jiménez, Alfons
  • Carolis, Carlo
  • Mayor, Alfredo
  • Izquierdo, Luis
  • Garcia Basteiro, Alberto L.
  • Moncunill, Gemma
  • Dobaño, Carlota
  • Gerhard, Markus
The ability of antibodies to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important correlate of protection. For routine evaluation of protection, however, a simple and cost-efficient anti-SARS-CoV-2 serological assay predictive of serum neutralizing activity is needed. We analyzed clinical epidemiological data and blood samples from two cohorts of health care workers in Barcelona and Munich to compare several immunological readouts for evaluating antibody levels that could be surrogates of neutralizing activity. We measured IgG levels against SARS-CoV-2 spike protein (S), its S2 subunit, the S1 receptor binding domain (RBD), and the full length and C terminus of nucleocapsid (N) protein by Luminex, and against RBD by enzyme-linked immunosorbent assay (ELISA), and assessed those as predictors of plasma surrogate-neutralizing activity measured by a flow cytometry assay. In addition, we determined the clinical and demographic factors affecting plasma surrogate-neutralizing capacity. Both cohorts showed a high positive correlation between IgG levels to S antigen, especially to RBD, and the levels of plasma surrogate-neutralizing activity, suggesting RBD IgG as a good correlate of plasma neutralizing activity. Symptomatic infection, with symptoms such as loss of taste, dyspnea, rigors, fever and fatigue, was positively associated with anti-RBD IgG positivity by ELISA and Luminex, and with plasma surrogate-neutralizing activity. Our serological assays allow for the prediction of serum neutralization activity without the cost, hazards, time, and expertise needed for surrogate or conventional neutralization assays. Once a cutoff is established, these relatively simple high-throughput antibody assays will provide a fast and cost-effective method of assessing levels of protection from SARS-CoV-2 infection. IMPORTANCE Neutralizing antibody titers are the best correlate of protection against SARS-CoV-2. However, current tests to measure plasma or serum neutralizing activity do not allow high-throughput screening at the population level. Serological tests could be an alternative if they are proved to be good predictors of plasma neutralizing activity. In this study, we analyzed the SARS-CoV-2 serological profiles of two cohorts of health care workers by applying Luminex and ELISA in-house serological assays. Correlations of both serological tests were assessed between them and with a flow cytometry assay to determine plasma surrogate-neutralizing activity. Both assays showed a high positive correlation between IgG levels to S antigens, especially RBD, and the levels of plasma surrogate-neutralizing activity. This result suggests IgG to RBD as a good correlate of plasma surrogate-neutralizing activity and indicates that serology of IgG to RBD could be used to assess levels of protection from SARS-CoV-2 infection., This work was supported by the European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Program. The study was also supported by the Institut de Salut Global de Barcelona (ISGlobal) internal funds, in-kind contributions from Hospital Clínic de Barcelona and the Fundació Privada Daniel Bravo Andreu. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. L.I. was supported by the PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia

  • Karachaliou, Marianna
  • Espinosa, Ana
  • Farré, Xavier
  • Blay, Natalia
  • Castaño Vinyals, Gemma
  • Iraola Guzmán, Susana
  • Rubio, Rocío
  • Vidal, Marta
  • Jiménez, Alfons
  • Bañuls, Marc
  • Aguilar, Ruth
  • García Aymerich, Judith
  • Dobaño, Carlota
  • Kogevinas, Manolis
  • Moncunill, Gemma
  • Cid Ibeas, Rafael de
Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment. Methods: The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses. Results: Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels. Conclusions: These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation., This work was funded by Incentius a l'Avaluació de Centres CERCA (in_ CERCA); EIT HEALTH BP2020-20873-Certify.Health.; Fundació Privada Daniel Bravo Andreu; PID2019-110810RB-I00 grant (Spanish Ministry of Science & Innovation). Rocio Rubio had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S). ISGlobal and IGTP receive support from the Generalitat de Catalunya through the CERCA Program. GCAT was funded by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026) and have additional suport by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529), National Grant PI18/01512 and VEIS project (001-P-001647) (co-funded by European Regional Development Fund (ERDF), “A way to build Europe”). This study was carried out using anonymized data provided by the Catalan Agency for Quality and Health Assessment, within the framework of the PADRIS Program. The funders had no role in the study design, data collection and analysis, interpretation of data, preparation of the manuscript, and decision to publish.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Long-term exposure to air pollution and COVID-19 vaccine antibody response in a general population cohort (COVICAT Study, Catalonia)

  • Kogevinas, Manolis
  • Karachaliou, Marianna
  • Espinosa, Ana
  • Aguilar, Ruth
  • Castaño Vinyals, Gemma
  • García Aymerich, Judith
  • Rubio, Rocío
  • Jiménez, Alfons
  • Vidal, Marta
  • Izquierdo, Luis
  • Cirach, Marta
  • Nieuwenhuijsen, Mark
  • Dadvand, Payam
  • Straif, Kurt
  • Moncunill, Gemma
  • Dobaño, Carlota
  • Tonne, Cathryn
Background: Ambient air pollution has been associated with COVID-19 disease severity and antibody response induced by infection. Objectives: We examined the association between long-term exposure to air pollution and vaccine-induced antibody response. Methods: This study was nested in an ongoing population-based cohort, COVICAT, the GCAT-Genomes for Life cohort, in Catalonia, Spain, with multiple follow-ups. We drew blood samples in 2021 from 1,090 participants of 2,404 who provided samples in 2020, and we included 927 participants in this analysis. We measured immunoglobulin M (IgM), IgG, and IgA antibodies against five viral-target antigens, including receptor-binding domain (RBD), spike-protein (S), and segment spike-protein (S2) triggered by vaccines available in Spain. We estimated prepandemic (2018-2019) exposure to fine particulate matter [PM ≤ 2.5μm in aerodynamic diameter (PM2.5)], nitrogen dioxide (NO2), black carbon (BC), and ozone (O3) using Effects of Low-Level Air Pollution: A Study in Europe (ELAPSE) models. We adjusted estimates for individual- and area-level covariates, time since vaccination, and vaccine doses and type and stratified by infection status. We used generalized additive models to explore the relationship between air pollution and antibodies according to days since vaccination. Results: Among vaccinated persons not infected by SARS-CoV-2 (n=632), higher prepandemic air pollution levels were associated with a lower vaccine antibody response for IgM (1 month post vaccination) and IgG. Percentage change in geometric mean IgG levels per interquartile range of PM2.5 (1.7μg/m3) were −8.1 (95% CI: −15.9, 0.4) for RBD,−9.9 (−16.2, −3.1) for S, and −8.4 (−13.5, −3.0) for S2. We observed a similar pattern for NO2 and BC and an inverse pattern for O3. Differences in IgG levels by air pollution levels persisted with time since vaccination. We did not observe an association of air pollution with vaccine antibody response among participants with prior infection (n=295). Discussion: Exposure to air pollution was associated with lower COVID-19 vaccine antibody response. The implications of this association on the risk of breakthrough infections require further investigation. https://doi.org/10.1289/EHP11989., We acknowledge support from the Incentius a l’Avaluació de Centres CERCA (in_CERCA); EIT HEALTH BP2020-20873-Certify.Health; Fundació Privada Daniel Bravo Andreu; Spanish Ministry of Science & Innovation (PID2019-110810RB-I00 grant); the Spanish State Research Agency and Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), the Instituto de Salud Carlos III (PI17/01555) and the Generalitat de Catalunya through the CERCA Program. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP. IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Department of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). G.M. is supported by RYC2020-029886-I/AEI/10.13039/501100011033, co-funded by European Social Fund. B.C. is supported by ISCIII national grant PI18/01512. R.R. is supported by the Health Department, Catalan Government (PERIS SLT017/20/000224). The full list of the investigators who contributed to the generation of the GCAT data is available from http://www.genomesforlife.com. Data are available from the authors.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multiplex antibody analysis of IgM, IgA and IgG to SARS-CoV-2 in saliva and serum from infected children and their close contacts

  • Dobaño, Carlota
  • Alonso, Selena
  • Vidal, Marta
  • Jiménez, Alfons
  • Rubio, Rocío
  • Santano, Rebeca
  • Barrios, Diana
  • Puyol, Laura
  • Baró, Bàrbara
  • Millat-Martínez, Pere
  • Ajanovic, Sara
  • Balanza, Núria
  • Arias, Sara
  • Rodrigo Melero, Natalia
  • Carolis, Carlo
  • Bassat, Quique
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Moncunill, Gemma
COVID-19 affects children to a lesser extent than adults but they can still get infected and transmit SARS-CoV-2 to their contacts. Field deployable non-invasive sensitive diagnostic techniques are needed to evaluate the infectivity dynamics of SARS-CoV-2 in pediatric populations and guide public health interventions, particularly if this population is not fully vaccinated. We evaluated the utility of high-throughput Luminex assays to quantify saliva IgM, IgA and IgG antibodies against five SARS-CoV-2 spike (S) and nucleocapsid (N) antigens in a contacts and infectivity longitudinal study in 122 individuals (52 children and 70 adults). We compared saliva versus serum/plasma samples in infected children and adults diagnosed by weekly RT-PCR over 35 days (n=62), and those who consistently tested negative over the same follow up period (n=60), in the Summer of 2020 in Barcelona, Spain. Saliva antibody levels in SARS-CoV-2 RT-PCR positive individuals were significantly higher than in negative individuals and correlated with those measured in sera/plasmas. Asymptomatic infected individuals had higher levels of anti-S IgG than symptomatic individuals, suggesting a protective anti-disease role for antibodies. Higher anti-S IgG and IgM levels in serum/plasma and saliva, respectively, in infected children compared to infected adults could also be related to stronger clinical immunity in them. Among infected children, males had higher levels of saliva IgG to N and RBD than females. Despite overall correlation, individual clustering analysis suggested that responses that may not be detected in blood could be patent in saliva, and vice versa. In conclusion, measurement of SARS-CoV-2-specific saliva antibodies should be considered as a complementary non-invasive assay to serum/plasma to determine COVID-19 prevalence and transmission in pediatric populations before and after vaccination campaigns., We are indebted to the Biobanc de l’Hospital Infantil Sant Joan de Déu per a la Investigació for the sample and data procurement. Some serum/plasma samples were tested against RBD protein produced in lentivirus by the P. Santamaria lab, IDIBAPS, and Jordi Chi contributed for production of N proteins (through PID2019-110810RB-I00 grant to LI).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain

  • Dobaño, Carlota
  • Alonso, Selena
  • Fernández de Sevilla, Mariona
  • Vidal, Marta
  • Jiménez, Alfons
  • Pons Tomas, Gemma
  • Jairoce, Chenjerai
  • Melé Casas, María
  • Rubio, Rocío
  • Hernández García, María
  • Ruiz-Olalla, Gemma
  • Girona-Alarcón, Mònica
  • Barrios, Diana
  • Santano, Rebeca
  • Mitchell, Robert A.
  • Puyol, Laura
  • Mayer, Leonie
  • Chi, Jordi
  • Rodrigo Melero, Natalia
  • Carolis, Carlo
  • Garcia-Miquel, Aleix
  • Bonet-Carne, Elisenda
  • Claverol, Joana
  • Cubells, Marta
  • Fortuny, Claudia
  • Fumado, Vicky
  • Jou, Cristina
  • Muñoz-Almagro, Carmen
  • Izquierdo, Luis
  • Bassat, Quique
  • Gratacós, Eduard
  • Aguilar, Ruth
  • García-García, Juan José
  • Moncunill, Gemma
  • Jordan, Iolanda
This work was supported by the Stavros Niarchos Foundation, Banco Santander, and other private donors through the Kids Corona Platform (Institut de Recerca Sant Joan de Deu), and the Fundació Privada Daniel Bravo Andreu. G.M. was supported by the Departament de Salut, Generalitat de Catalunya (grant number SLT006/17/00109). L.I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C). ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program., Background: Surveillance tools to estimate viral transmission dynamics in young populations are essential to guide recommendations for school opening and management during viral epidemics. Ideally, sensitive techniques are required to detect low viral load exposures among asymptomatic children. We aimed to estimate SARS-CoV-2 infection rates in children and adult populations in a school-like environment during the initial COVID-19 pandemic waves using an antibody-based field-deployable and non-invasive approach. Methods: Saliva antibody conversion defined as ≥ 4-fold increase in IgM, IgA, and/or IgG levels to five SARS-CoV-2 antigens including spike and nucleocapsid constructs was evaluated in 1509 children and 396 adults by high-throughput Luminex assays in samples collected weekly in 22 summer schools and 2 pre-schools in 27 venues in Barcelona, Spain, from June 29th to July 31st, 2020. Results: Saliva antibody conversion between two visits over a 5-week period was 3.22% (49/1518) or 2.36% if accounting for potentially cross-reactive antibodies, six times higher than the cumulative infection rate (0.53%) assessed by weekly saliva RT-PCR screening. IgG conversion was higher in adults (2.94%, 11/374) than children (1.31%, 15/1144) (p=0.035), IgG and IgA levels moderately increased with age, and antibodies were higher in females. Most antibody converters increased both IgG and IgA antibodies but some augmented either IgG or IgA, with a faster decay over time for IgA than IgG. Nucleocapsid rather than spike was the main antigen target. Anti-spike antibodies were significantly higher in individuals not reporting symptoms than symptomatic individuals, suggesting a protective role against COVID-19. Conclusion: Saliva antibody profiling including three isotypes and multiplexing antigens is a useful and user-friendlier tool for screening pediatric populations to detect low viral load exposures among children, particularly while they are not vaccinated and vulnerable to highly contagious variants, and to recommend public health policies during pandemics., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and cytokine profile

  • Rubio, Rocío
  • Aguilar, Ruth
  • Bustamante Pineda, Mariona
  • Muñoz, Erica
  • Vázquez-Santiago, Miquel
  • Santano, Rebeca
  • Vidal, Marta
  • Rodrigo Melero, Natalia
  • Parras, Daniel
  • Serra, Pau
  • Santamaria, Pere
  • Carolis, Carlo
  • Izquierdo, Luis
  • Gómez Roig, Ma. Dolores
  • Dobaño, Carlota
  • Moncunill, Gemma
  • Mazarico, Edurne
SARS-CoV-2 infected pregnant women are at increased risk of severe COVID-19 than non-pregnant women and have a higher risk of adverse pregnancy outcomes like intrauterine/fetal distress and preterm birth. However, little is known about the impact of SARS-CoV-2 infection on maternal and neonatal immunological profiles. In this study, we investigated the inflammatory and humoral responses to SARS-CoV-2 in maternal and cord blood paired samples. Thirty-six pregnant women were recruited at delivery at Hospital Sant Joan de Déu, Barcelona, Spain, between April-August 2020, before having COVID-19 available vaccines. Maternal and pregnancy variables, as well as perinatal outcomes, were recorded in questionnaires. Nasopharyngeal swabs and maternal and cord blood samples were collected for SARS-CoV-2 detection by rRT-PCR and serology, respectively. We measured IgM, IgG and IgA levels to 6 SARS-CoV-2 antigens (spike [S], S1, S2, receptor-binding domain [RBD], nucleocapsid [N] full-length and C-terminus), IgG to N from 4 human coronaviruses (OC43, HKU1, 229E and NL63), and the concentrations of 30 cytokines, chemokines and growth factors by Luminex. Mothers were classified as infected or non-infected based on the rRT-PCR and serology results. Sixty-four % of pregnant women were infected with SARS-CoV-2 (positive by rRT-PCR during the third trimester and/or serology just after delivery). None of the newborns tested positive for rRT-PCR. SARS-CoV-2 infected mothers had increased levels of virus-specific antibodies and several cytokines. Those with symptoms had higher cytokine levels. IFN-α was increased in cord blood from infected mothers, and in cord blood of symptomatic mothers, EGF, FGF, IL-17 and IL-15 were increased, whereas RANTES was decreased. Maternal IgG and cytokine levels showed positive correlations with their counterparts in cord blood. rRT-PCR positive mothers showed lower transfer of SARS-CoV-2-specific IgGs, with a stronger effect when infection was closer to delivery. SARS-CoV-2 infected mothers carrying a male fetus had higher antibody levels and higher EGF, IL-15 and IL-7 concentrations. Our results show that SARS-CoV-2 infection during the third trimester of pregnancy induces a robust antibody and cytokine response at delivery and causes a significant reduction of the SARS-CoV-2-specific IgGs transplacental transfer, with a stronger negative effect when the infection is closer to delivery., This work was supported by the Fundació Privada Daniel Bravo Andreu. RR had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). LI work was supported by the PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. We acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasmodium falciparum apicomplexan-specific glucosamine-6-phosphate n-acetyltransferase is key for amino sugar metabolism and asexual blood stage development

  • Planas, Antoni
  • Leivar, Pablo
  • Chi, Jordi
  • Cova, Marta
  • De las Rivas, Matilde
  • Medina, Ana
  • Junqueira Borges, Rafael
  • Usón, Isabel
  • Hurtado-Guerrero, Ramón
  • Izquierdo, Luis
ABSTRACT UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1. The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria., IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite’s ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sustained seropositivity up to 20.5 months after COVID-19

  • Dobaño, Carlota
  • Ramírez Morros, Anna Maria
  • Alonso, Selena
  • Rubio, Rocío
  • Ruiz-Olalla, Gemma
  • Vidal Alaball, Josep
  • Macià, Dídac
  • Miró Catalina, Queralt
  • Vidal, Marta
  • Fuster Casanovas, Aina
  • Prados de la Torre, Esther
  • Barrios, Diana
  • Jiménez, Alfons
  • Zanoncello, Jasmina
  • Rodrigo Melero, Natalia
  • Carolis, Carlo
  • Izquierdo, Luis
  • Aguilar, Ruth
  • Moncunill, Gemma
  • Ruiz-Comellas, Anna
This study evaluated the persistence of IgM, IgA, and IgG to SARS-CoV-2 spike and nucleocapsid antigens up to 616 days since the onset of symptoms in a longitudinal cohort of 247 primary health care workers from Barcelona, Spain, followed up since the start of the pandemic. The study also assesses factors affecting antibody levels, including comorbidities and the responses to variants of concern as well as the frequency of reinfections. Despite a gradual and significant decline in antibody levels with time, seropositivity to five SARS-CoV-2 antigens combined was always higher than 90% over the whole study period. In a subset of 23 participants who had not yet been vaccinated by November 2021, seropositivity remained at 95.65% (47.83% IgM, 95.65% IgA, 95.65% IgG). IgG seropositivity against Alpha and Delta predominant variants was comparable to that against the Wuhan variant, while it was lower for Gamma and Beta (minority) variants and for IgA and IgM. Antibody levels at the time point closest to infection were associated with age, smoking, obesity, hospitalization, fever, anosmia/hypogeusia, chest pain, and hypertension in multivariable regression models. Up to 1 year later, just before the massive roll out of vaccination, antibody levels were associated with age, occupation, hospitalization, duration of symptoms, anosmia/hypogeusia, fever, and headache. In addition, tachycardia and cutaneous symptoms associated with slower antibody decay, and oxygen supply with faster antibody decay. Eight reinfections (3.23%) were detected in low responders, which is consistent with a sustained protective role for anti-spike naturally acquired antibodies. Stable persistence of IgG and IgA responses and cross-recognition of the predominant variants circulating in the 2020-2021 period indicate long-lasting and largely variant-transcending humoral immunity in the initial 20.5 months of the pandemic, in the absence of vaccination., The study received support from the Fundació Privada Daniel Bravo Andreu. Development of SARS-CoV-2 RBD was partially supported by the NIAID CEIRS contract HHSN272201400008C. L.I. work was supported by PID2019-110810RB-I00. E.P. was supported by a grant from the Junta de Andalucía/EU. R.R. had the support of the Health Department, Catalan Government (PERIS SLT017/20/000224). ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. Funders were not involved in the study conduct, manuscript preparation, or submission.